Low-dose atropine eyedrops no higher than placebo for slowing myopia development

Use of low-dose atropine eyedrops (focus 0.01%) was no higher than placebo at slowing myopia (nearsightedness) development and elongation of the attention amongst kids handled for 2 years, in response to a randomized managed trial. The trial aimed to determine an efficient strategy to handle this main and more and more widespread explanation for refractive error, which might trigger severe uncorrectable imaginative and prescient loss later in life.